TABLE 3.
Ibrutinib | Control | |
---|---|---|
B-cell malignancies (%) | 71/2,357 (3.0%) | 30/1931 (1.6%) |
CLL (%) | 44/1727 (2.5%) | 14/1,299 (1.1%) |
First-line (%) | 39/1,577 (2.5%) | 11/1,182 (0.9%) |
Relapsed/refractory (%) | 29/725 (4.0%) | 16/674 (2.4%) |
The percentage (%) is calculated from the events/total number of patients. CLL, chronic lymphocytic leukemia.